title: Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management.
authors.affiliation: Department of infectious and communicable diseases, Hôpital Saint-Antoine, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France. odile.picard@sat.aphp.fr
authors.forename: Odile
authors.initials: O
authors.lastname: Picard
authors.forename: Patrice
authors.initials: P
authors.lastname: Cacoub
mesh_terms: D003875:Drug Eruptions / Q000209:etiology*; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D009842:Oligopeptides / Q000009:adverse effects*; D011392:Proline / Q000009:adverse effects / Q000031:analogs & derivatives*; D011480:Protease Inhibitors / Q000009:adverse effects*
chemical_list: D009842:Oligopeptides; D011480:Protease Inhibitors; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline